Optimizing Dose Intensity of Treatment for Patients With Metastatic Renal Cell Carcinoma

Activity Goals

Outline

VEGF TKIs for mRCC

Case 1

Case 1: Treatment Options

Case 1: Enrolled in a Clinical Trial

Case 1 (cont)

Case 2

Case 2 (cont)

Early Adverse Effects of TKIs

Late Adverse Effects of TKIs

Management Strategies for Hand-Foot Skin Reaction

Management Strategies for Hand-Foot Skin Reaction (cont)

Management Strategies for Hand-Foot Skin Reaction (cont)

Management of Hypertension

Management of Hypertension (cont)

Gastrointestinal SymptomsNausea/Dyspepsia/Diarrhea Management

Stomatitis and Cheilitis: Mouth

Hair Depigmentation/Skin Discoloration

Hypothyroidism

Fatigue Assessment

Sunitinib: Drug Interactions

Case 3

Case 3 (cont)

Rationale for Individualized Dose/Schedule Changes

Dose-Limiting Toxicities

Improved PFS and OS in Patients With Sunitinib-Related Toxicity

Clinical Outcomes in Patients With mRCC Who Were Treated With Alternative Schedules

Individualizing Sunitinib Therapy

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)